Our fourth quarter edition features leading insights from subject matter experts covering a range of cutting-edge scientific topics, including microbiome therapy, biofabrication, cell and gene therapy, antibody–drug conjugates (ADCs), high-potency APIs, next-generation chromatography, personalized medicine and the increasingly complex “zoo” of multifunctional antibody and protein formats.
Nigel Walker, Managing Director of That's Nice, provides an overview of the current state of the industry with regard to gene therapy, highlighing recent advances and ongoing challenges.
Health Bowers, Technical Business Director for Pharmaceutical Sciences, North America, at ABITEC, discusses recent advances in the oral delivery of peptides.
Mark Bamforth, founder and CEO of Arranta Bio, explains the establishment as the company as a CDMO dedicated to producing live biotherapeutic products for the treatment of microbiome-based diseases.
Yourway President Gulam Jaffer explains how the company's integrated global courier network and clinical packaging services accelerate clinical trials.
A flexible approach to analytical methods is key to solving process challenges, according to Shaonly Saha, Analytical Development Scientist -- MS&T Analytical at Grifols Recombinant Protein CDMO Services.
Julie Risdon, Business Director Pharma Solutions, and Megan Duffy, Program Manager, explain how Albemarle Fine Chemistry Services adheres to project milestones to ensure on time and in full delivery.
Associate Director of Manufacturing Tyler Ewald describes UPM Pharmaceuticals' support for commercial projects at all scales.
Ian Markwell, Vice President of Quality at Almac Pharma Services, relates Almac's successful completion of three regulatory inspections within two weeks and how that illustrates the company's commitment to quality.
Servier has developed a comprehensive corporate social responsibility strategy with benefits to all stakeholders, explains CSR Director Vincent Minvielle.
Growing demand for parenteral products led PCI Pharma Services to invest in a Center of Excellence for injectables packaging, according to Alex Weaver, Director of Engineering & HSSE, and Dave Christmas, Principal Engineer.
ProQR Therapeutics is taking a novel approach to treating inherited retinal diseases with intravitreal RNA therapies, according to Founder and CEO Daniel de Boer.
Tim Tench, Senior Project Manager, discusses how CRB's OneSolution process fast tracks facility design and construction, reducing timelines to get novel medicines to patients more quickly.
Bernie Sweeney, R&D Director Cell Expression Systems at Lonza Pharma & Biotech, provides an overview of the growing "zoo" of novel protein formats, including bi- and multispecific antibodies.
Evolving 3D bioprinting technologies will soon facilitate the biofabrication of tissues and organs for transplant and other uses, according to Brian Berquist, Robert Erwin, and Tom Isett of iBio.
Significant advances in the purification of monoclonal antibodies will be made possible by high-producutivity membrane chromatography technologies, explains Gary Skarja, Head of Membrane Chromatography R&D at MIlliporeSigma.
An introduction to our feature on the promise and challenges of gene therapy.
The Nice Insight team highlights recent R&D innovations driving the field of gene therapy.
The rapid advancement of cell and gene therapies through clinical trials is creating an acute need for scalable production technologies.
The growth of the market for gene and particularly gene-modified cell therapies is putting new demands on the temperature-controlled supply chain, explain the Nice Insight editorial team.
My Personal Therapeutics Founder and CEO Laura Towart reviews some of the technologies driving personalized medicine.
George Hlass, Senior Director of Business Development for APIs, and David Bastie, Commercial Project Coordinator at Fareva explain the strategic advantages of partnering with a commercial-scale CDMO from the start of HPAPI programs.
Business Development Manager Matteo Piazza explains how the PROVEO Alliance combines the strengths of AGC Biologics, Cerbios, and Oncotec Pharma Produktion to provide streamlined, integrated support for ADC programs.
Nice Insight's Cynthia Challener provides a comprehensive overview of applications of blockchain technology in the pharma industry.
Protalix Biotherapeutics President and CEO Dror Bashan explains the company's unique plant cell-based expression system.
Andrea Pfeifer, CEO of AC Immune, discusses novel immunological approaches to diagnosis and treatment of Alzheimer's disease.
Novel linker technology may be critical to increasing the potency and effectiveness of ADCs, explains Philipp Spycher, Co-Founder and CEO of Araris Biotech.
Reducing neural overactivity may be key to preventing the progression of Alzheimer's disease, according to Michaela Gallagher, Founder and CEO of AgeneBio.
Douglas W. Losordo, Executive Vice President, Global Head of R&D, and Chief Medical Officer of Caladrius Biosciences, discusses the promise of CD34+ cell therapies for cardiovascular disease.
CAR-T therapies using natural killer cells have considerable potential to treat both hematological cancers and solid tumors, accoding to Filippo Petti, CEO of Celyad.
Purnanand Sarma, President and CEO of Immunome, explains the company's unique high-throughput approach to identify novel antibody-target pairs.
Ocugen Chairman, CEO and Co-Founder Shankar Musunuri discusses the company's approach to developing drugs for high-need ophthalmic diseases.
Photodynamic therapy presents a novel approach to the unmet need for bladder cancer patients, says Shawn Shirazi, CEO of Theralase Technologies.
A strategic partnership with a used equipment supplier can significantly reduce costs and time to equip a facility for a fast-tracked program, discusses Justin Kadis of Federal Equipment Company.
Lydia Michaut, Scientific Officer at BioAgilytix, explains the significance of the first clinical trial using CRISPR-Cas9 gene-editing technology.
Peter Scholes, CSO at Quotient Sciences, discusses the time and cost savings associated with their Translational Pharmaceutics offering, which integrates formulation, real-time manufacturing and clinical testing.
RIchard Richieri, COO, and Magnus Schroeder, VP of Process Development at Avid BIoservices, discuss the advantages of choosing a single CDMO for the entire life cycle.
Stephen P. Adams, Product Manager for Flexicon at Watson-Marlow Fluid Technology Group, discusses fill-finish solutions for small-batch drug products.
Robert Reames, Director of Technical Operations at Aldevron, provides an overview of the historical role of plasmids in drug development and their future potential.
Behavioral interviewing is a critical tool in matching candidates and positions, according to Dave Kerns, Managing Partner at Key Corporate Services.
With a new facility acquisition, Labomar is fully entering the North American market, explains Founder and CEO Walter Bertin.
A range of experts speculate on the technologies likely to transform the industry in the coming year.
This roundtable features SMEs discussing the most important technological breakthroughs of the past year.
.svg)
